04/29/2026
A Genetic Bridge Across the Atlantic: Why APOL1 is the Key to Global Kidney Equity. In my work, I have seen the devastating impact of kidney disease on Black individuals across both the U.S. and sub-Saharan Africa. While the healthcare settings differ, the underlying biological driver is often the same: the APOL1 gene.
This gene is a remarkable example of an evolutionary trade-off. It developed to protect our ancestors from the deadly African Sleeping Sickness, but today, it has become a primary driver of the kidney disease epidemic in people of African descent.
The Global Data (2026 Update):
• In the United States: Approximately 15% of African Americans carry the high-risk genotype (two copies), while 50% carry at least one variant.
• In West Africa: In countries like Nigeria and Ghana, the risk is even more concentrated. High-risk genotypes can reach up to 23–28% of the population.
• The Regional Contrast: Interestingly, these variants are nearly absent (